Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)
Lockhart, Pauline; Daly, Fergus; Pitkethly, Marie; Comerford, Natalia; Sullivan, Frank

Published in:
Cochrane Database of Systematic Reviews

DOI:
10.1002/14651858.CD001869.pub4

Publication date:
2010

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):
Lockhart, P., Daly, F., Pitkethly, M., Comerford, N., & Sullivan, F. (2010). Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews, (4), -. [CD001869].
https://doi.org/10.1002/14651858.CD001869.pub4
Antiviral treatment for Bell’s palsy (idiopathic facial paralysis) (Review)

Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 6

http://www.thecochranelibrary.com

Antiviral treatment for Bell’s palsy (idiopathic facial paralysis) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
# Table of Contents

**HEADER** ................................................. 1
**ABSTRACT** .................................................. 1
**PLAIN LANGUAGE SUMMARY** .................................. 2
**BACKGROUND** ............................................... 2
**OBJECTIVES** ................................................. 3
**METHODS** ................................................... 3
**RESULTS** ..................................................... 4
  - Figure 1. ..................................................... 6
  - Figure 2. ..................................................... 8
  - Figure 3. ..................................................... 9
  - Figure 4. ..................................................... 9
**DISCUSSION** ................................................. 10
**AUTHORS’ CONCLUSIONS** ..................................... 11
**ACKNOWLEDGEMENTS** ........................................ 12
**REFERENCES** ............................................... 12
**CHARACTERISTICS OF STUDIES** .............................. 14
**DATA AND ANALYSES** ....................................... 23
  - Analysis 1.1. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 1 Incomplete recovery at end of study. ........................................... 24
  - Analysis 1.2. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 2 Motor synkinesis or crocodile tears. ........................................... 25
  - Analysis 1.3. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 3 Adverse Events. ........................................... 25
  - Analysis 2.1. Comparison 2 Antivirals versus corticosteroids, Outcome 1 Incomplete recovery at end of study. ........................................... 26
  - Analysis 2.2. Comparison 2 Antivirals versus corticosteroids, Outcome 2 Motor synkinesis at end of study. ........................................... 26
  - Analysis 2.3. Comparison 2 Antivirals versus corticosteroids, Outcome 3 Adverse Events. ........................................... 27
  - Analysis 3.1. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 1 Incomplete recovery at end of study. ........................................... 27
  - Analysis 3.2. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 2 Adverse Effects. ........................................... 28
**ADDITIONAL TABLES** ......................................... 28
**APPENDICES** .................................................. 30
**WHAT’S NEW** ................................................ 33
**HISTORY** .................................................... 33
**CONTRIBUTIONS OF AUTHORS** ............................... 34
**DECLARATIONS OF INTEREST** ............................... 34
**SOURCES OF SUPPORT** ....................................... 34
**DIFFERENCES BETWEEN PROTOCOL AND REVIEW** ............... 34
**INDEX TERMS** ................................................ 35
[Intervention Review]

Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)

Pauline Lockhart1, Fergus Daly1, Marie Pitkethly2, Natalia Comerford3, Frank Sullivan1

1Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education, University of Dundee, Dundee, UK. 2Centre for Primary Care and Population Research, Division of Clinical & Population Sciences & Education, University of Dundee, Dundee, UK. 3Dundee, UK

Contact address: Pauline Lockhart, Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, UK. P.Lockhart@cpse.dundee.ac.uk.

Editorial group: Cochrane Neuromuscular Disease Group.
Publication status and date: Edited (no change to conclusions), published in Issue 6, 2010.
Review content assessed as up-to-date: 24 February 2009.


Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Antiviral agents against herpes simplex virus are widely used in the treatment of idiopathic facial paralysis (Bell’s palsy), but their effectiveness is uncertain. Significant morbidity can be associated with severe cases.

Objectives
This review addresses the effect of antiviral therapy on Bell’s palsy.

Search methods
We updated the search of the Cochrane Neuromuscular Disease Group Trials Register (December 2008), MEDLINE (from January 1966 to December 8 2008), EMBASE (from January 1980 to December 8 2008) and LILACS (from January 1982 to December 2008).

Selection criteria
Randomized trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell’s palsy.

Data collection and analysis
Twenty-three papers were selected for consideration.

Main results
Seven trials including 1987 participants met the inclusion criteria, adding five studies to the two in the previous review.

Incomplete recovery at one year. There was no significant benefit in the rate of incomplete recovery from antivirals compared with placebo (n = 1886, RR 0.88, 95% CI 0.65 to 1.18). In meta-analyses with some unexplained heterogeneity, the outcome with antivirals was significantly worse than with corticosteroids (n = 768, RR 2.82, 95% CI 1.09 to 7.32) and the outcome with antivirals plus corticosteroids was significantly better than with placebo (n = 658, RR 0.56, 95% CI 0.41 to 0.76).

Motor synkinesis or crocodile tears at one year. In single trials, there was no significant difference in long term sequelae comparing antivirals and corticosteroids with corticosteroids alone (n = 99, RR 0.39, 95% CI 0.14 to 1.07) or antivirals with corticosteroids (n = 101, RR 1.03, 95% CI 0.51 to 2.07).
Adverse events. There was no significant difference in rates of adverse events between antivirals and placebo (n = 1544, RR 1.06, 95% CI 0.81 to 1.38), between antivirals and corticosteroids (n = 667, RR 0.96, 95% CI 0.65 to 1.41) or between the antiviral-corticosteroid combination and placebo (n = 658, RR 1.15, 95% CI 0.79 to 1.66).

Authors’ conclusions

High quality evidence showed no significant benefit from anti-herpes simplex antivirals compared with placebo in producing complete recovery from Bell’s palsy. Moderate quality evidence showed that antivirals were significantly less likely than corticosteroids to produce complete recovery.

PLAIN LANGUAGE SUMMARY

Antiviral treatment for Bell’s palsy

Bell’s palsy is a disease of the facial nerve which causes one side of the face to be paralysed. Some studies have suggested that it is caused by infection with the cold sore (herpes simplex) virus. If this is correct, antiviral drugs against herpes simplex would be likely to help recovery. It has also been suggested that corticosteroids may help. The paralysis is usually temporary even when untreated, although without treatment about one person in five is left with permanent facial disfigurement or pain.

This updated review provided high quality evidence that antivirals are no more effective than placebo (dummy) treatment in producing complete recovery. On the other hand moderate quality evidence showed that antivirals were less effective than corticosteroids and that combined antiviral-corticosteroid treatment were more effective than placebo. Taken together, these results suggest that corticosteroids might be effective but this requires confirmation from the Cochrane review of corticosteroids which is being updated. There was no evidence that antivirals produced significantly more or significantly fewer adverse events than dummy treatment.

As this analysis shows that antivirals against the cold sore virus are not significantly effective, other causes for Bell’s palsy than infection by the cold sore virus now need to be considered.

BACKGROUND

Bell’s palsy is an acute unilateral paralysis of the facial nerve first described by the Scottish surgeon Sir Charles Bell (1774 to 1842) (Petruzelli 1991). It affects 11 to 40 people per 100,000 in the population per annum, most commonly in the age group 30 to 45 (Bateman 1992; Brandenberg 1993; Katusic 1986; Pietersen 1982; Pietersen 2002; Yanagihara 1988). The condition presents disproportionately amongst pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, every year a British general practitioner will see one or two people who have developed the condition. A UK study using the general practice research database (GPRD) showed that 36% of people were treated with oral corticosteroids and 19% were referred to hospital (Rowlands 2002). Although most recover well, 30% of people with Bell’s palsy have a poor recovery with continuing facial disfigurement, psychological difficulties and sometimes facial pain (though the presence and course of pain is unclear from current knowledge) (Morgenlander 1990). The aetiology has yet to be established but genetic, vascular, infectious and immunological causes have all been postulated (Adour 1996). Animal studies have suggested the possibility that reactivation of herpes viruses may be responsible for demyelination (Morgan 1995; Sugita 1995). Herpes simplex virus, has been implicated as a cause in several studies (McCormick 1972; Murakami 1996; Stjernquist-Desatnik 2006; Takasu 1992; Theil 2001). Infection with this virus is thought to cause inflammation of the facial nerve. Treatment has commonly been based on this hypothesis. Antiviral medication is supposed to eradicate the infectious agent and corticosteroids to reduce the swelling of the facial nerve.

The previous versions of the Cochrane reviews concerning the treatment of Bell’s palsy examined the effectiveness of oral prednisolone and aciclovir (Allen 2007; Salinas 2002). These found that insufficient data exist to conclude that either or both therapies are effective. Many of the studies mentioned in these reviews but excluded from the analysis either failed to randomize participants or, when correctly randomized, were erroneously interpreted in a favourable light (May 1976; Wolf 1978). In addition, high dose corticosteroid therapy has numerous potential side effects including peptic ulceration hypertension and confusional states. Antivi-
Antiviral therapy is expensive and should be reserved for circumstances where definite benefits are likely to be obtained. Previous recommendations suggested that aciclovir needs to be started within 48 hours, although a study of viral replication in participants with Bell's palsy suggested that the window might be extended (Abiko 2002).

Since publication of the previous versions of the Cochrane reviews, large scale, randomized controlled trials of antivirals and corticosteroids have been published necessitating substantive updates of the reviews.

**OBJECTIVES**

The objective of the review was to determine the effectiveness of anti-herpes simplex antiviral treatments for Bell's palsy. We selected as outcome variables (i) recovery status measured by conventional validated instruments and (ii) presence of motor synkinesis or crocodile tears. A third outcome variable, adverse effects of treatment, was also collected. Other symptoms (pain, discomfort and embarrassment) have been reported as outcomes in some trials but were not considered in this review.

**METHODS**

**Criteria for considering studies for this review**

Types of studies

We searched for all randomized or quasi-randomized (alternate or other systematic allocation) controlled trials involving aciclovir, valaciclovir or famciclovir alone or in combination with any other therapy in the treatment of Bell's palsy.

Types of participants

We considered all trials where participants were diagnosed with unilateral facial paralysis of unknown cause, and who satisfied the authors' requirements for eligibility and inclusion.

Types of interventions

We considered all trials where treatment was undertaken with any oral antiviral licensed for the treatment of herpes simplex infections in immunocompetent participants. The list comprised aciclovir, valaciclovir, a pro-drug of aciclovir and famciclovir, a prodrug of penciclovir. We considered trials where participants received antiviral therapy versus placebo or any other treatment.

**Types of outcome measures**

The outcome measures have been modified since the previous review to take into account the heterogeneity of this group of studies. Where outcome measures were measured 'at six months', this has been replaced by 'at the end of the study'. Duration of studies included in this review ranges from three months to 12 months: this method allows maximum data inclusion.

Incomplete recovery has been altered to include the range of definitions used by the studies included to allow maximum data capture: as opposed to the previous definition of moderate dysfunction, the term now includes participants with a lack of full function. More participants will be classified as 'incomplete recovery' by this definition.

'Adverse events attributable to antiviral treatment' has been replaced with 'adverse events': in studies where both agents are administered it is difficult to assess which agent is causing the adverse event. Similarly, even when only an antiviral is being prescribed, it is difficult to know whether a specific event should be attributed to the medication or another intercurrent cause. The level of detailed analysis of adverse events in studies did not permit such a judgement being made.

**Primary outcomes**

Incomplete recovery of facial function at the end of study measured using a validated rating scale.

**Secondary outcomes**

1. Motor synkinesis or crocodile tears at the end of the study.
2. Complete facial paralysis at the end of the study.
3. Adverse events.

**Search methods for identification of studies**

In this updated review, we searched the Cochrane Neuromuscular Disease Group Trials register (December 2008), MEDLINE (January 1966 to December 8 2008), EMBASE (January 1980 to December 8 2008) and LILACS (January 1982 to December 2008). We also reviewed the bibliographies of the identified trials, contacted trial authors and known experts in the field and contacted relevant drug companies to identify additional published or unpublished data. For MEDLINE, EMBASE and LILACS database search strategies please see Appendix 1, Appendix 2 and Appendix 3.

**Data collection and analysis**

All five authors scrutinised the search databases to determine papers for inclusion. At least two authors independently assessed
each paper for relevance, eligibility and quality. There were no disagreements about inclusion.

In the first version of this review four possible trials were identified but only two qualified for inclusion. The number of references retrieved from each source was not stated. A search at the update in April 2003 generated 49 papers in EMBASE, 22 in MEDLINE and 15 in LILACS but no new trials were identified. Our new search in 2008 identified 68 papers in EMBASE, 26 in MEDLINE and 3 in LILACS. From this search, 23 papers were selected for review of the full text and five trials were subsequently included in addition to those which were included in the previous version of the review.

We considered each trial design and whether it was randomized, method of randomization to treatment, dosage of all treatment comparisons (amount, frequency, duration and route of administration), whether the trial was placebo-controlled, blinded (for treatment administrator, patient and assessment of recovery status) or unstated, and for definition of recovery status. All five authors were given a selection of papers to read, review for quality and extract data from. Each trial was assessed by at least two authors. PL completed the risk of bias table which was individually reviewed by FS and FD. All five authors agreed data extraction. Two authors (PL and FD) agreed input into Review Manager (RevMan, the programme provided by the Cochrane Collaboration).

Three of the trial authors were contacted for additional information and two responded with data. A previous review author was contacted for updated information on other studies and a response was received.

Assessment of bias was conducted by scoring studies using the risk of bias methods described in the 2008 version of the Cochrane Handbook, according to Cochrane methods.

We calculated a weighted treatment effect using the Mantel-Haenszel method (Egger 2007). The random effects model was used where there was marked heterogeneity between studies (Chi² test, P < 0.1, I² > 50%). The fixed-effect model was used where heterogeneity was not detected with standard statistical methods.

When comparing studies which use differing symptom scores to assess outcome, we used the House-Brackmann grading system and the Sunnybrook scale. Two, three, six and 12 months. Disease status was measured using the House-Brackmann grading system and the Sunnybrook scale. When assessing adverse events, the number of participants affected, as opposed to the number of events was used to facilitate data comparison.

As in previous editions of this review, the meta-analysis outcomes have been reported for both studies which compare antivirals either with or without corticosteroids to corticosteroids and those studies which compare antivirals only to corticosteroids only. We have conducted three comparisons: antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids and antivirals plus corticosteroids versus no treatment plus corticosteroids), antivirals versus corticosteroids and antivirals plus corticosteroids versus placebo.

Sensitivity analysis has been used to assess the effects of combining trials with and without additional treatments in the analysis of antivirals versus placebo and the impact of length of follow up on the meta-analysis results.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification.

Five randomized controlled trials with 1787 participants in total were added to the previous version of this review which had two trials and 200 participants. All five trials provided a comparison of disease outcome after antiviral treatment with disease outcome after an otherwise identical treatment regimen lacking the antiviral component. One thousand nine hundred and eighty-seven participants were included in the seven included studies. Engelstrom (Engström 2008) recruited 829 participants to be treated within 72 hours of onset and randomized by a computerised mechanism in a two-stage process into four treatment groups: valaciclovir with prednisolone or valaciclovir with placebo or placebo with prednisolone or double placebo in a factorial design. The trial was blinded for administrator, patient and assessment of recovery status until the end of follow-up. Participants were assessed at onset, after two weeks (11 to 17 days), after one, two, three, six and 12 months. Disease status was measured using the House-Brackmann grading system and the Sunnybrook scale. Recovery status was defined by a Sunnybrook score of 100 and a House-Brackman grade of 1. Time to recovery was estimated. Data analysis included an assessment of treatment interaction.

The study reported no effect on recovery time due to valaciclovir (P = 0.76). Recovery rates at 12 months were 57.5% in the valaciclovir group compared with 57.3% in the placebo group (P = 1.00). For this review, we aggregated the antiviral plus corticosteroid with the antiviral plus placebo group and the corticosteroid plus placebo with the double placebo group to achieve the most powerful comparison for the effect of treatment with valaciclovir on recovery rates at 12 months. We analysed these recovery rates 12 months after palsy onset from their results. With complete recovery defined as a Sunnybrook score of 100, 271 out of 413 recovered with valaciclovir compared with 266 out of 416 recovered without valaciclovir, RR 1.03. With complete recovery defined as a House-Brackmann grade of 1, 297 out of 413 recovered with valaciclovir compared with 293 out of 416 without valaciclovir, RR 1.02.

Hato (Hato 2007) randomized 296 participants within seven days of onset using sealed envelopes into two treatment groups: valaciclovir with prednisolone or placebo with prednisolone. Two hundred and twenty-one participants were included in the final anal-
ysis. The administrators were not blinded to the treatment allocation but the participants were blinded to treatment received. Those assessing recovery status were not blinded to treatment. Participants’ disease severity was assessed using the Yanagihara scale and were assessed as completely recovered if attaining a score greater than 36. Participants were assessed at onset and monthly thereafter for six months or until completely recovered if recovery occurred before six months.

The group reported significant benefit from treatment with antivirals and corticosteroids compared to corticosteroids alone: recovery in the group receiving valaciclovir and prednisolone was seen in 110/114 and recovery in the placebo and prednisolone group was seen in 96/107, RR 1.08 at six months after palsy onset. Kawaguchi (Kawaguchi 2007) recruited 150 participants to be treated within seven days of onset and randomized using sealed envelopes into two treatment groups: valaciclovir with prednisolone or prednisolone alone. Thus we deduce that there was no blinding for administrator or participant. Participants were assessed at onset using both the Yanagihara 40-point scale and House-Brackmann index. Recovery was measured using only the Yanagihara index (36 or more). Recovery time in days was recorded. Follow up was scheduled for one week, two weeks and one, two, three, four, five and six months.

This trial reported no significant difference in recovery rate between the prednisolone group and the prednisolone-aciclovir group at six months.

Sullivan (Sullivan 2007) recruited 551 participants to be treated within 72 hours of onset and randomized by a dedicated remote telephone-computerised mechanism in a two-stage process into four treatment groups: aciclovir with prednisolone (AS) or aciclovir with placebo (AO) or placebo with prednisolone (OS) or double placebo (OO) in a factorial design. The trial was blinded for administrator, participant and assessment of recovery status until the end of follow-up. Participants were assessed at onset, after three months, and if still unwell at three months, after nine months. Recovery status was measured using the House-Brackmann scale with complete recovery defined by House-Brackmann grade I. Data analysis included an assessment of treatment interaction.

Sullivan (Sullivan 2007) reported final outcomes on 496 completed participants at three months and nine months and shows a beneficial effect of not receiving antivirals. The nine month recovery rates were 211 out of 247 in the aciclovir group compared with 226 out of 249 among participants not receiving aciclovir, RR 0.92.

Yeo (Yeo 2008) recruited 91 participants with Bell’s palsy who were randomized to receive either aciclovir and prednisolone or prednisolone alone. All participants also received physical therapy and plasma volume expanders as adjuncts. The trial was double blind and participants were followed up for six months or until complete recovery. Recovery was assessed using the House-Brackmann scale and defined as a House-Brackmann score of 2 or less.

Yeo (Yeo 2008) reported outcomes for 91 participants at two and six months. There was no significant difference in recovery between the two treatment groups. The six month recovery rate in the antiviral and corticosteroids group was 44 out of 44 and in the corticosteroids only group 40 out of 47, RR 1.17.

Details of other studies previously included in this review are given below.

Adour (Adour 1996) recruited 119 participants of whom 99 were included in the published analysis. The study was double-blind and placebo-controlled. Participants were recruited within three or less days since the onset of paralysis and received either aciclovir and prednisolone or placebo and prednisolone. The study duration was four months and participants were reviewed at two weeks, two months and four months. This was a single centre study. The Facial Paralysis Recovery Index (FPRl) was used to measure facial function and the primary trial outcome was incomplete recovery defined by an FPRl 7 or less.

This study reported significant benefit of treatment with aciclovir plus corticosteroids compared with corticosteroids alone, RR 1.22 after four months.

De Diego (De Diego 1998) recruited 113 participants and included 101 in the final analyses. Participants were randomly assigned treatment: blinding status was not clear. Evaluation was carried out within 48 hours of the onset of symptoms and participants received either aciclovir for 10 days or prednisolone for 16 days (reducing dose). Reviews were scheduled for one, three, six and 12 weeks after initial contact with further contact if persistent incomplete recovery was noted. The primary study outcome was recovery as defined using the House-Brackmann and facial paralysis recovery profile scales. Full recovery was defined as a House-Brackman score of 2 or less or a Facial Paralysis Recovery Profile (FPFP) of 8 or more. The final length of follow-up is not reported but stated as ‘until complete recovery or stabilization of the paralysis’.

This study reported significant treatment benefit in the corticosteroids only group, RR 0.83.

We have changed the status of the Antunes (Antunes 2000) study for this report from ‘included’ to ‘excluded’. The authors of the previous edition of this review initially included it but found the data to be incomplete and, despite attempting to contact the authors, there was not sufficient information for the data to be usefully included in the analyses.

We have reassessed the inclusion of the two studies awaiting assessment (P de Aquino 2001; Roy 2005). The author of the previous version of this review, Dr. D. Allen, tried to contact the author of the former paper for clarification of the data, but this has not been forthcoming and so we have excluded this trial because of a lack of adequate information. The latter study appeared as an abstract in a journal supplement and has not, according to the search strategies employed, been published as a full paper. Again, this trial has been excluded due to a lack of adequate information. A further study awaits classification (Inanli 2001). This was in-
cluded in a recently published systematic review and meta-analysis (Goudakos 2009). We await translation and interpretation. Updated status of this paper will be included in the next update of the Cochrane Review.

**Risk of bias in included studies**

The risk of bias is summarised in Figure 1.

**Figure 1. Risk of bias summary: review authors’ judgments about each risk of bias domain for each included study.**
Sequence generation, allocation concealment and blinding

Three studies (Adour 1996; Engström 2008; Sullivan 2007) were randomized, double-blind and placebo-controlled to minimise the effects of bias. Kawaguchi (Kawaguchi 2007) described a randomized study but states that the treatment was revealed to the clinician and the absence of a placebo made treatment clear to the recipient. The remaining two studies (De Diego 1998; Hato 2007) all described randomization but not blinding or placebo use. Yeo (Yeo 2008) stated that their study was randomized and double-blind: this was not within the text and so this study has been graded as unclear for these attributes.

Incomplete outcome data

All studies, except Yeo (Yeo 2008) reported frequencies, and often reasons, for failure to complete follow-up. Most trials (Engström 2008; Kawaguchi 2007; De Diego 1998; Sullivan 2007; Yeo 2008) reported a drop-out rate of 10% or less except Adour 1996, 16.8% and Hato 2007, 19%.

Selective outcome reporting

All studies, except Adour 1996 reported all their intended primary outcomes. Adour failed to report on audiometry and stapedial reflex testing. Engström 2008 reported all primary outcomes and stated that secondary outcomes will be reported in a later paper.

Other potential sources of bias

Diagnostic criteria

Six studies (De Diego 1998; Engström 2008; Hato 2007; Kawaguchi 2007; Sullivan 2007; Yeo 2008) gave adequate information. All studies explicitly mentioned a diagnosis of Bell's palsy and stated that other causes of facial palsy had been considered and excluded. Two trials (Hato 2007; Kawaguchi 2007) retrospectively excluded participants on the basis of positive serology for herpes simplex (HSV) or varicella zoster (VZV) viruses. Two studies (Engström 2008; Sullivan 2007) mention referral to specialists for diagnostic confirmation.

The remaining study Adour 1996 stated participants were diagnosed with Bell's palsy but did not give any further information.

Outcome criteria

All studies used referenced facial scoring systems to grade recovery from facial paralysis. Adour (Adour 1996) used the Facial Paralysis Recovery Profile (FPRP) and the Facial Paralysis Recovery Index (FPRI). (Adour 1971). Hato (Hato 2007) and Kawaguchi (Kawaguchi 2007) used the Yanagihara scoring system (Yanagihara 2003), which has a validated system for conversion to the House-Brackmann scale (House 1985). De Diego (De Diego 1998) presented results using the FPRP and House-Brackmann scale (House 1985). Engstrom, Sullivan and Yeo (Engström 2008; Sullivan 2007; Yeo 2008) presented results using the House-Brackmann scale (House 1985) and Engstrom supplemented this using the Sunnybrook scale (Ross 1996) to minimise the effects of inter-rater variability.

Statistical analysis

Six out of the seven studies analysed gave adequate detail: they clearly stated and then used appropriate statistical tests. Only Hato (Hato 2007) scored unclear in this category as the tests used were not stated.

Differences in baseline between groups

Six out of the seven trials were adequate in this category. De Diego (De Diego 1998) found a significant difference in rates of hypertension between the two groups: further analysis revealed that there was no significant difference in trial outcomes as a result. Kawaguchi (Kawaguchi 2007) reported a significant difference between mean age of the treatment groups but further analysis of the age distribution using the Chi² test revealed no significant difference. In the tables in the other studies, no significant differences between the baseline groups were reported.

Effects of interventions

As all trials reported different intervals and lengths of follow up lengths, the analyses were performed on data reported at the end of the study periods of three months (De Diego 1998), four months (Adour 1996), six months (Hato 2007; Kawaguchi 2007; Yeo 2008) nine months (Sullivan 2007) or 12 months (Engström 2008) after the start of treatment.

Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids and antivirals plus corticosteroids versus no treatment plus corticosteroids)

This comparison contained six studies (Adour 1996; Engström 2008; Hato 2007; Kawaguchi 2007; Sullivan 2007 and Yeo 2008) with 1886 participants in total. The relative rate of incomplete recovery at the end of the study did not show a significant difference between treatment with antiviral and treatment with placebo, the RR of incomplete recovery being 0.88 (95% CI 0.65 to 1.18), Analysis 1.1 and Figure 2. Heterogeneity was high when the fixed-effect model was used (Chi² = 11.78, P 0.04, I² 58%), the random-effects model was used to partially correct for this.
We analysed two subgroups of these trials. Two trials (Engström 2008 and Sullivan 2007) provided data for both these comparisons. For the six trials with altogether 1228 participants, which compared antivirals plus corticosteroids with corticosteroids plus placebo or no treatment, (Adour 1996; Engström 2008; Hato 2007; Kawaguchi 2007; Sullivan 2007 and Yeo 2008), there was a significant but slight reduction in the rate of incomplete recovery, RR 0.64 (0.50 to 0.82), favouring the combination of antivirals and corticosteroids over corticosteroids alone. For two trials (Engström 2008 and Sullivan 2007) which compared antivirals with placebo without any complicating additional treatment, there were 658 participants and the relative rate of incomplete recovery was again non-significant, RR 1.14 (95% CI 0.82 to 1.59). One study comparing antivirals and corticosteroids with corticosteroids alone (Adour 1996) had data for the outcome motor synkinesis or crocodile tears at the end of the study, Analysis 1.2. This included 99 participants and showed no significant difference between antivirals and corticosteroids, RR 0.47 (95% CI 0.20 to 1.07).

Adverse events were slightly, but not significantly, less likely with antiviral treatment than without, Analysis 1.3, RR 1.06 (95% CI 0.81 to 1.38). This analysis included data from three studies (Engström 2008; Hato 2007 and Sullivan 2007) and 1544 participants.

**Antivirals versus corticosteroids**

This comparison contained three studies (De Diego 1998; Engström 2008 and Sullivan 2007) with 768 participants in total. All three studies gave data for our primary outcome, recovery at the end of the study. Incomplete recovery was significantly less common in the participants treated with antivirals than those treated with corticosteroids. Initial calculations using the fixed-effect model showed RR 1.96 (95% CI 1.48 to 2.59) but with a high degree of heterogeneity (Chi² 8.78, P = 0.01, I² 77%). The analysis was repeated using the random-effects model to partially correct for this, Analysis 2.1 and Figure 3, RR 2.82 (95% CI 1.09 to 7.32).
De Diego (De Diego 1998) alone reported motor synkinesis or crocodile tears at the end of the study. This analysis contains data on 101 participants and showed no significant difference between antiviral and corticosteroid, the RR being only 1.03 (95% CI 0.51 to 2.07), Analysis 2.2.

Adverse event data were available from the Sullivan 2007 and Engström 2008 trials. There was no significant difference between the groups, with RR 0.96 (95% CI 0.65 to 1.41) fewer participants with adverse events in the antivirals than the placebo groups, Analysis 2.3.

Antivirals plus corticosteroids versus placebo

This comparison contained two studies (Engström 2008; Sullivan 2007) and outcome data on 658 participants. Incomplete recovery at the end of the study was significantly much less common with the combined treatment than placebo, Analysis 3.1 and Figure 4, RR 0.56 (95% CI 0.41, 0.76). This analysis had low heterogeneity (Chi² 0.14, I² 0.0%).

Sensitivity analyses

We investigated the effects of using the comparison antivirals plus corticosteroids, placebo or no treatment versus corticosteroids, placebo or no treatment by performing further analyses to investigate whether our conclusions were altered when studies with a follow-up of less than six months were excluded (De Diego 1998 and Adour 1996) and when only outcomes reported at greater than six months were included (Engström 2008 and Sullivan 2007). Further sensitivity analysis was performed to assess the potential difference in participant response to aciclovir (Adour 1996, De Diego 1998, Kawaguchi 2007, Sullivan 2007 and Yeo 2008) versus valaciclovir (Engström 2008 and Hato 2007).
When Adour 1996 was excluded, the RR of incomplete recovery was 0.94 (95% CI 0.71 to 1.26, n = 1787). When Adour 1996; Hato 2007; Kawaguchi 2007 and Yeo 2008 were excluded, the RR of incomplete recovery was 1.06 (95% CI 0.83 to 1.35, n = 1325). This represents no significant change seen with the removal of outcomes which followed up at six months or less.

When sensitivity analysis was performed to assess the differing response to aciclovir and valaciclovir, no significant difference was found. Overall the RR for aciclovir was 0.93 (95% CI 0.45 to 1.90, n = 686) in an analysis which included data from three trials. Overall the RR for valaciclovir was 0.87 (95% CI 0.66 to 1.14, n = 1200) in an analysis including data from three trials.

**Antivirals versus corticosteroids**

When the De Diego 1998 study was excluded and the analysis was just performed with Engström 2008 and Sullivan 2007, the relative risk of more benefit with antivirals than with corticosteroids, for the outcome incomplete recovery at the end of the study, was no longer significant, RR 2.69 (95% CI 0.73 to 10.01, n = 667). This study differed in reporting outcome at less than six months and its exclusion changed the conclusion of the meta-analysis from “significant” to “non-significant”.

Sensitivity analysis assessing the differing response to aciclovir versus valaciclovir did not alter the overall conclusion from the meta-analysis. The respective results were RR aciclovir 4.68 (95% CI 2.25 to 9.74, n = 351) with data from two trials and valaciclovir RR 1.50 (95% CI 1.11 to 2.03, n = 417) with data from one trial.

**Antiviral plus corticosteroid versus placebo**

There was no change in the data for this analysis, based on Engström 2008 and Sullivan 2007. This represents no significant effect from excluding studies, which report the outcome incomplete recovery at the end of the study, which report at less than 6 months.

Sensitivity analysis looking at aciclovir and valaciclovir both resulted in a change to these results. For aciclovir, with data from one trial, the RR was 0.49 (95% CI 0.23 to 1.05, n = 246) and for valaciclovir, again with data from one trial, the RR was 0.58 (95% CI 0.41 to 0.80, n = 412). In both cases, this represents a loss of significance in the difference between outcomes for antivirals plus corticosteroids versus placebo.

**Discussion**

This updated review resolves much of the uncertainty about the value of herpes simplex antivirals for Bell’s palsy. There was no evidence of significant benefit from antivirals in comparison with placebo but they were significantly less efficacious than corticosteroids.

When antivirals were compared to placebo, there was little difference in the recovery of participants receiving either treatment RR 0.88 (95% CI 0.65 to 1.18). This result was influenced by the Sullivan 2007 trial which suggested that antiviral treatment had a non-significant detrimental effect on recovery: 27 out of 122 participants receiving antivirals had incomplete recovery compared to 18 out of 122 participants receiving placebo, RR 1.48 (95% CI 0.87 to 2.56). A possible reason is that, although active against the presumed infective agent, antiviral medication causes increased local inflammation and exacerbation of symptoms (Jarisch-Herxheimer reaction).

When antiviral treatment was compared to corticosteroid treatment, the participants receiving corticosteroid treatment were significantly more likely to recover than those receiving antiviral treatment: that is, there was more incomplete recovery in the antiviral group RR 2.82 (95% CI 1.09 to 7.32). This analysis displayed significant heterogeneity which was not fully corrected by applying the random-effects model and needs to be interpreted with caution.

Similarly, the outcome was significantly better in the participants receiving corticosteroid and antiviral treatment compared with placebo: that is the RR of incomplete recovery was significantly less, 0.56 (95% CI 0.41 to 0.76), in those who received combined treatment.

The RR of incomplete recovery, calculated using the fixed-effects model, was significantly less 0.75 (95% CI 0.57 to 0.98) with the combined treatment than with corticosteroids alone which would suggest a beneficial effect from antivirals but this analysis showed moderate heterogeneity and should be interpreted with caution.

The source of heterogeneity may be due to clinical variation for example in study participant characteristics, disease severity at baseline, delay in receiving treatment or type of antiviral agent used. Equally, variation may be due to methodological considerations such as method of randomization, the use of blinding, the choice of outcome assessment measures and recovery cut-off points or the trial duration. In particular, Hato 2007 and Kawaguchi 2007 had methodological weaknesses in baseline group assessment, completeness of follow-up and adequate blinding. Any of these factors could result in bias and introduce inaccuracy. The heterogeneity was exacerbated by keeping the inclusion criteria fairly broad: this maximises data inclusion and therefore power, but results must be interpreted with this in mind.

Sensitivity analysis of trials with data with less than a six month end-point showed results similar to those achieved with the whole group analysis - no significant effect of shortened time of follow up was detected.

Similarly, sub-group analysis of the relative treatment difference with different antivirals showed no significant change in the antivirals versus placebo or antivirals versus corticosteroids results.
In the antivirals plus corticosteroids comparison, the examination of individual therapy removed the significant difference in incomplete outcome. Given this, it is unlikely that different antivirals, despite the difference in bioavailability (Sullivan 2007), will have a significant affect on the outcome of incomplete recovery at the end of the study.

Given that a significant benefit in terms of incomplete recovery at end of study was derived from the combination of antivirals plus corticosteroids, this may merit further investigation. It may be that the use of prednisolone suppresses the Jarish-Harrheimer reaction and allows the antiviral treatment to provide some benefit.

There were insufficient data to examine any other variables which are reported in the studies, such as pain, quality of life and variation in response due to time to treatment and severity at onset. These variables can be used as hypothesis generation for future work in this area.

From the minimal data available for comparison of motor synkinesis or crocodile tears at the end of the study, the results of two studies with separate comparisons with a total number of participants of 200 were not significant. De Diego (De Diego 1998) compared antivirals with corticosteroids and found fewer episodes of these outcomes in the corticosteroids group while Adour (Adour 1996) compared antivirals and corticosteroids and found fewer episodes of these outcomes in the antiviral treatment group. Relatively low participant numbers and a degree of clinical (different clinical assessment scales used) and methodological heterogeneity (different treatment regimes and follow up plans) limit the interpretation of these data.

No data were available in any of the studies to assess the outcome 'complete paralysis at the end of the study'.

Adverse events data were available in three studies (Engström 2008; Hato 2007 and Sullivan 2007) giving comparison data on 1544 participants. None of the comparisons showed significant differences in adverse events between either arm. No correlation with specific treatment could be found within these results.

There has been variation in the clinical end-points chosen as defining recovery: Engstrom and Sullivan (Engström 2008; Sullivan 2007) use House-Brackmann (H-B) Grade 1: Yeo used H-B Grade 2. The other studies used a variety of different scales which show more or less equivalence to these. Additional information is attached which give details of the symptoms scales and comparison where available (Table 1; Table 2; Table 3)

Age at onset, either as an independent predictor of recovery or as a predictor or treatment response might be an important variable: Kawaguchi (Kawaguchi 2007) stratified for age and noted a significantly lower recovery rate in 40 to 60 year olds compared to those under 40 years old.

Neither Kawaguchi (Kawaguchi 2007) nor Yeo (Yeo 2008) found a significant association between time to treatment and final recovery status.

There were differences in severity at recruitment: several studies were based in secondary care (Hato 2007; Kawaguchi 2007 and Yeo 2008) and so may have included a more severe spectrum of palsy than those based within primary care. Hato and Kawaguchi (Hato 2007; Kawaguchi 2007) stratified by severity of disease status at onset and found that in cases of complete or severe palsy the recovery rate for the combination treatment was significantly greater than that for the corticosteroid only group.

Studies conducted in Asia, North America and Europe, have been included. It is possible that genetic differences in drug metabolism or response or even different aetiological processes may account some of the variation in response which is observed.

The other important consideration which is raised by the primary outcome result are the health economic issues: a 10 day course of aciclovir 400 mg five times daily costs GBP 9.28; valaciclovir and famciclovir equivalent courses cost significantly more; a 10 day course of prednisolone (25 mg tablets daily), costs about GBP 7.14 (BNF 2008). These cost data are specific to the current UK market and costs vary significantly in other countries (Hernández 2008).

Further work in this area could address the questions raised by the possible causes of heterogeneity in some of the comparisons in this review and may be achieved through a combination of epidemiological work and further large randomized controlled trials which collect comparable data for sub-group analysis and meta-regression.

AUTHORS' CONCLUSIONS

Implications for practice

High quality evidence from randomized controlled trials of herpes simplex antivirals for the treatment of Bell's palsy showed no significant benefit from antivirals compared to placebo. High quality evidence showed significant benefit from the combination of antivirals and corticosteroids compared with placebo. Moderate quality evidence showed significantly less benefit from antivirals than corticosteroids. There was no significant increase in adverse events from antivirals compared with either placebo or corticosteroids.

Implications for research

The results cast doubt on previous hypotheses suggesting herpes simplex as the cause of Bell's palsy and research should be aimed at discovering alternative causes.

More work is needed to assess the likelihood of long term cosmetic sequelae. Sub-group analysis of existing data and future studies
should be done to assess the impact of variables such as time from diagnosis until treatment received, severity of palsy at baseline and age of patient at presentation on the outcome. Work assessing softer end-points such as quality of life and perceived disability should be done to develop better understanding of Bell's palsy at the patient level.

ACKNOWLEDGEMENTS

Dr J Sipe, Mrs L Dunn and Dr D Allen authored the previous editions of this review and we are very grateful for their hard work and enthusiasm. Furthermore, Dr D Allen communicated with Dr P Lockhart and assisted with clarification of the status of some studies. Our thanks are also extended to the Cochrane Neuromuscular Disease Group for their extensive technical assistance and support.

REFERENCES

References to studies included in this review

Adour 1996 {published data only}


De Diego 1998 {published data only}


Engström 2008 {published data only}


Hato 2007 {published data only}


Kawaguchi 2007 {published and unpublished data}


Sullivan 2007 {published and unpublished data}


Yeo 2008 {published data only}


References to studies excluded from this review

Ahangar 2006 {published data only}


Antunes 2000 {published data only (unpublished sought but not used)}


Axelsson 2003 {published data only}


Chen 2005 {published data only}


Hato 2003 {published data only}


Hultcrantz 2005 {published data only}


Ibarrondo 1999 {published data only}

References to studies awaiting assessment

Inanli 2001  [published data only]

Additional references

Abiko 2002

Adour 1971

Allen 2007

Bateman 1992

BNF 2008

Brandenberg 1993

Egger 2007

Goudakos 2009

Hernández 2008

House 1985

Katusic 1986

May 1976

McCormick 1972

Morgan 1995

Morgenlander 1990

Murakami 1996

Petruzelli 1991

Pietersen 1982
Characteristics of included studies  [ordered by study ID]

Adour 1996

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>119 randomized, 99 included in published analysis. Initial diagnosis of idiopathic facial paralysis in primary care clinics or emergency departments confirmed in facial paralysis research clinic. Enrolment criteria: paralysis commenced &lt;= 3 days before treatment; all participants over 18 years of age; good physical health determined by history and physical exam; no contraindication for steroid or aciclovir treatment; all women of childbearing age had a negative pregnancy test result.</td>
</tr>
<tr>
<td>Interventions</td>
<td>Aciclovir (2000 mg per day for 10 days) and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for remaining 5 days) or placebo and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for remaining 5 days)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary outcome: recovery on facial paralysis recovery index where incomplete recovery is Facial Paralysis Recovery Profile (FPRP) &lt;=7 at 4 months. Maximal stimulation test +/- electroneurography at follow up at 2 weeks, 2 months, 3 months and 4 months (if incomplete recovery after paralysis onset). Final outcomes reported at 3 months or when recovered or palsy stabilized (not more clearly defined).</td>
</tr>
<tr>
<td>Notes</td>
<td>Single centre. Exclusion criteria: no other medication for idiopathic facial paralysis, urea nitrogen or creatinine &gt; 2x upper limit of normal, liver transaminase &gt; 3x upper limit of normal; haemoglobin level &lt;100 g/L; platelet count &lt; 75 000/mm3; or neutrophil count &lt;1 x 10 to the 6/L</td>
</tr>
</tbody>
</table>

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Quote “the bottles [of aciclovir and placebo], provided by Burroughs Wellcome, were randomised in groups of 10”.</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>Quote “Each bottle...had a sealed identification label which was removed intact and kept with the patient’s record”.</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>Yes</td>
<td>Quote “eligible patients were given identical, unlabeled bottles of 100 capsules that contained either placebo or aciclovir (Zovirax), 200 mg”. Patients in each group received identical follow-up.</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>Yes</td>
<td>The study is reported as double blind: the method reported is consistent with being able to achieve this.</td>
</tr>
<tr>
<td>Incomplete outcome data?</td>
<td>Yes</td>
<td>The numbers of participants unable to complete the study is given.</td>
</tr>
</tbody>
</table>
Selective outcome reporting? No  Primary outcome of facial paralysis recovery profile and bilateral facial nerve electrical testing both reported but no data given on audiometry with stapedial reflex testing

Other sources of bias? No  Single centre study High drop out rate reported - 16.8% Diagnostic criteria not clearly defined in paper

De Diego 1998

Methods  Participants randomly assigned. No further details given.

Participants  113 participants randomized, 101 included in published analysis. Evaluation within first 96 hours. No contraindications to corticosteroid or aciclovir

Interventions  Aciclovir (2400 mg per day for 10 days) or prednisone (1 mg/kg for 10 days then tapered to zero over next 6 days)

Outcomes  Primary outcome: recovery using House-Brackman facial nerve grading scale and facial paralysis recovery profile (FPRP) (Adour 1971). Where recovery was defined as H-B score <= 2 or FPRP >= 8. Denervation reported with maximal stimulation test and electromyography in severe cases. Sequelae and synkinesis recorded separately Follow up at 1, 3, 6, 12 weeks after first visit. Participants with incomplete recovery at 12 weeks followed until recovery made or stabilisation of paralysis Final outcomes reported at 4 months.

Notes  Single centre. Both House-Brackman and FPRP scales used.

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Unclear</td>
<td>Quote “Patients were randomly assigned”.</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>No</td>
<td>No clear information but unlikely to be true as no indication of blinding - see below</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>No</td>
<td>Presence of blinding not clearly stated but unlikely to be the case as groups receive different treatment regimens (corticosteroids once daily or aciclovir three times daily) with no clear method for concealing this difference</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>Unclear</td>
<td>This is not mentioned in the study.</td>
</tr>
<tr>
<td>Incomplete outcome data?</td>
<td>Yes</td>
<td>Number lost to follow up reported.</td>
</tr>
</tbody>
</table>
### De Diego 1998

<table>
<thead>
<tr>
<th>Selective outcome reporting?</th>
<th>Yes</th>
<th>All desired outcomes reported.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other sources of bias?</td>
<td>No</td>
<td>Single centre study.</td>
</tr>
</tbody>
</table>

### Engström 2008

**Methods**

Participants randomized by computerised mechanism in a two-stage process into four treatment groups: valaciclovir with prednisolone (AS), valaciclovir with placebo (AO), placebo with prednisolone (OS) or double placebo (OO).

**Participants**

829 participants randomized within 72 hours of facial palsy onset. No contraindications to corticosteroids or antivirals use.

**Interventions**

Participants allocated into one of four treatment groups as described above and received a combination of valaciclovir 1000 mg three times daily for 7 days +/- prednisolone 60 mg daily for 5 days.

**Outcomes**

Primary outcome: recovery of facial function, as assessed at all visits with the Sunnybrook Scale and the House-Brackmann Scale. Where complete recovery was taken as Sunnybrook scale 100 or H-B grade 1.

Degree of pain as recorded during the first 2 months and adverse events were recorded for the first month. *Borrelia burgdorferi* serology was measured at baseline and 2 months. Frequency of severe pain, synkinesis, facial spasm and residual facial symptoms at 12 months is recorded.

Follow up at 2 weeks, 1 month, 2 months 3 months, 6 months and 12 months after randomization according to recovery.

Final outcomes reported at 12 months.

**Notes**

Multi-centre. Sunnybrook and House-Brackman scales used.

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Quote “...randomization code was developed by Glaxo Wellcome GmbH, with a computer number generator to select random permuted blocks of eight”</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>Randomization code double-blind and held by third party - medication dispensed in identical containers according to allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>Yes</td>
<td>Study drugs issued in identical containers. All participants blinded to treatment group until study completion</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>Yes</td>
<td>All study personnel and data analysts blinded to treatment group until study completion</td>
</tr>
</tbody>
</table>
### Engström 2008  (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data?</th>
<th>Yes</th>
<th>Numbers lost to follow up and reasons for this given.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective outcome reporting?</td>
<td>Yes</td>
<td>Secondary outcomes listed but not reported: all primary outcomes reported. Other outcomes will be reported in another paper due to space constrictions</td>
</tr>
<tr>
<td>Other sources of bias?</td>
<td>Yes</td>
<td>No other potential sources of bias identified.</td>
</tr>
</tbody>
</table>

### Hato 2007

#### Methods
Random allocation to 2 groups to receive either valaciclovir and prednisolone (VP) or placebo and prednisolone (PP). Using the 'envelope' method

#### Participants
296 participants randomized; 152 participants to VP, 144 participants to PP. All participants commenced treatment within 7 days of onset of palsy. All participants over 15 years and had no contraindications to antivirals or corticosteroids. 221 patients were included in the final analysis

#### Interventions
Randomized to receive prednisolone 60 mg for 5 days, 30 mg for 3 days and 10 mg for 2 days +/- valaciclovir 1000 mg/day for 5 days. All participants received mecobalamin 1500 micrograms per day following corticosteroids for 6 months or until complete recovery

#### Outcomes
Primary outcome full recovery based on a score of >= 36 on the Yanagihara scale. Follow up at 1,3 and 6 months after commencing treatment. Final outcomes reported at 6 months.

#### Notes
Multi-centre: 6 academic tertiary referral centres. Measurements using Yanagihara scale - conversion scale to House-Brackmann scale included in paper

#### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Quote “the patients were randomly divided into two groups using the envelope method”</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>No</td>
<td>Allocation was only concealed until intervention assigned.</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>No</td>
<td>Inadequate. Participants blinded to treatment but different treatments with different frequencies mean true blinding was not achieved</td>
</tr>
<tr>
<td>Incomplete outcome data?</td>
<td>Yes</td>
<td>Participants who did not complete the study have frequency and reason for drop out documented</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Selective outcome reporting?</td>
<td>Yes</td>
<td>Main outcome measures all reported.</td>
</tr>
<tr>
<td>Other sources of bias?</td>
<td>No</td>
<td>High drop out rate reported - 19%. Statistical tests employed not clearly stated.</td>
</tr>
</tbody>
</table>

**Kawaguchi 2007**

**Methods**
Random allocation to receive either prednisolone or prednisolone and valaciclovir. Using the 'envelope' method.

**Participants**
150 participants: 66 prednisolone, 84 prednisolone and valaciclovir. All participants received treatment within 7 days from onset of palsy. All participants aged 15 or older and had no contraindications to corticosteroids or antivirals.

**Interventions**
Participants received 20 mg three times daily for days 1 to 5, then 10 mg three times daily days 6 to 8, then 10 mg daily days 9 and 10 +/- valaciclovir 500 mg twice a day for 5 days.

**Outcomes**
Facial movement and recovery measured using the Yanagihara scale where complete recovery was taken as a score of >= 36. Virological examination for presence of antiHSV and VZV antibodies and detection of HSV and VZV reactivation. Frequency of incomplete recovery at end of study and adverse events recorded but not published - information obtained from author (by PL) Follow up for 6 months at 1 and 2 weeks after treatment and then at 1, 2, 3, 4, 5 and 6 months after treatment. Final outcomes reported at 6 months.

**Notes**
Multi-centre: 12 university hospitals. Yanagihara rating scale.

**Risk of bias**

<table>
<thead>
<tr>
<th><strong>Item</strong></th>
<th><strong>Authors’ judgement</strong></th>
<th><strong>Description</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Sequence generation using envelope method.</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>No</td>
<td>Not used - when entered in the trial, the allocation envelope contains the name of the treatment group</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>No</td>
<td>Not done.</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>No</td>
<td>Not done.</td>
</tr>
</tbody>
</table>
**Kawaguchi 2007 (Continued)**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data?</td>
<td>Yes</td>
<td>Numbers of participants who did not complete clearly documented</td>
</tr>
<tr>
<td>Selective outcome reporting?</td>
<td>Yes</td>
<td>All primary outcomes reported.</td>
</tr>
<tr>
<td>Other sources of bias?</td>
<td>Yes</td>
<td>No other potential sources of bias identified.</td>
</tr>
</tbody>
</table>

**Sullivan 2007**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Double-blind, placebo-controlled randomized, factorial trial. Participants allocated to one of four treatment groups to receive either aciclovir, prednisolone, both agents or placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>551 participants randomized and 496 included in final outcomes assessment. Referred for assessment and treatment within 72 hours of paralysis onset. All participants aged 16 or older and no contraindications to corticosteroids or antivirals</td>
</tr>
<tr>
<td>Interventions</td>
<td>Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg five times daily for 10 days, both or neither depending upon allocation</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary outcome measure was recovery rated on House-Brackmann scale where recovery was a score of H-B grade 1. Secondary outcomes included health-related quality of life, Health Utilities Index Mark 3, facial appearance (Derriford appearance scale) pain and adverse outcomes. Frequency of incomplete recovery at end of study was recorded. Follow up at 3 and 9 months. Final outcomes reported at 9 months.</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Yes</td>
<td>Quote “...patient was randomly assigned to a study group by an independent, secure, automated telephone randomization service.”</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>All parties blinded to allocation.</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>Yes</td>
<td>Participants not receiving active drug given placebo. All administered medication identical and in identical containers</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>Yes</td>
<td>Assessors blinded to treatment group.</td>
</tr>
<tr>
<td>Incomplete outcome data?</td>
<td>Yes</td>
<td>All participants who were unable to complete are documented - both frequency and reason</td>
</tr>
</tbody>
</table>
### Selective outcome reporting?

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate sequence generation?</td>
<td>Unclear</td>
<td>States randomized in study title but no description of this in the article</td>
</tr>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>No clear statement of this in the study.</td>
</tr>
<tr>
<td>Blinding of participants?</td>
<td>Unclear</td>
<td>States double-blind in study title but no description of methods employed for this in text</td>
</tr>
<tr>
<td>Blinding of assessors?</td>
<td>Unclear</td>
<td>States double-blind in study title but no description of methods employed for this in text</td>
</tr>
<tr>
<td>Incomplete outcome data?</td>
<td>Unclear</td>
<td>Incomplete follow-up data is not mentioned in the study.</td>
</tr>
<tr>
<td>Selective outcome reporting?</td>
<td>Yes</td>
<td>Stated primary outcome measure reported.</td>
</tr>
<tr>
<td>Other sources of bias?</td>
<td>No</td>
<td>Single centre study. All participants admitted. Biased towards cases of severe palsy.</td>
</tr>
</tbody>
</table>
**Characteristics of excluded studies**  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahangar 2006</td>
<td>No random allocation to treatment groups.</td>
</tr>
<tr>
<td>Antunes 2000</td>
<td>Not enough information in original paper. Author contacted by Dr D Allen but no response received</td>
</tr>
<tr>
<td>Axelsson 2003</td>
<td>Use of a historical control group.</td>
</tr>
<tr>
<td>Chen 2005</td>
<td>Follow up data for four weeks from palsy onset only.</td>
</tr>
<tr>
<td>Hultcrantz 2005</td>
<td>No random allocation to treatment groups.</td>
</tr>
<tr>
<td>Ibarrondo 1999</td>
<td>Retrospective study. One hundred participants collected between 1983 and 1989 received corticotherapy. One hundred participants treated after 1989 received aciclovir</td>
</tr>
<tr>
<td>P de Aquino 2001</td>
<td>Methodology not clear from original paper. Authors contacted by D Allen but no response. Confirmed by contacting D Allen in 2008 (PL)</td>
</tr>
<tr>
<td>Ramos Macias 1992</td>
<td>Inadequate allocation concealment. No information reported about methods of randomization; the diagnostic criteria used; the length of follow-up or number of participants lost to follow-up</td>
</tr>
<tr>
<td>Roy 2005</td>
<td>Inadequate information: abstract only published in journal supplement and not traced as a full publication</td>
</tr>
<tr>
<td>Zhou 1999</td>
<td>Prospective study. Sixty-nine participants with Bell’s palsy followed up for 2 weeks only. Not double-blind and allocation concealment not described. Used own scale for palsy grading, outcome measures not met. Did report adverse events. Four aciclovir treatment participants had gastric malaise</td>
</tr>
</tbody>
</table>

**Characteristics of studies awaiting assessment**  [ordered by study ID]

**Inanli 2001**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Prospective, controlled, randomized study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>42 participants</td>
</tr>
<tr>
<td>Interventions</td>
<td>20 treated with aciclovir plus prednisone, 22 treated with prednisone alone</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Neural regeneration</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>
### DATA AND ANALYSES

Comparison 1. Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete recovery at end of study</td>
<td>6</td>
<td>1886</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.88 [0.65, 1.18]</td>
</tr>
<tr>
<td>1.1 Antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids</td>
<td>6</td>
<td>1228</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.71 [0.48, 1.05]</td>
</tr>
<tr>
<td>1.2 Antivirals versus placebo</td>
<td>2</td>
<td>658</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.14 [0.80, 1.62]</td>
</tr>
<tr>
<td>Motor synkinesis or crocodile tears</td>
<td>1</td>
<td>99</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.47 [0.20, 1.07]</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>3</td>
<td>1544</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.06 [0.81, 1.38]</td>
</tr>
</tbody>
</table>

Comparison 2. Antivirals versus corticosteroids

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete recovery at end of study</td>
<td>3</td>
<td>768</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>2.82 [1.09, 7.32]</td>
</tr>
<tr>
<td>Motor synkinesis at end of study</td>
<td>1</td>
<td>101</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.03 [0.51, 2.07]</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>2</td>
<td>667</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.96 [0.65, 1.41]</td>
</tr>
</tbody>
</table>

Comparison 3. Antivirals plus corticosteroids versus placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete recovery at end of study</td>
<td>2</td>
<td>658</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.56 [0.41, 0.76]</td>
</tr>
<tr>
<td>Adverse Effects</td>
<td>2</td>
<td>658</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.15 [0.79, 1.66]</td>
</tr>
</tbody>
</table>
**Analysis 1.1. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 1 Incomplete recovery at end of study.**

Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)

Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)

Outcome: 1 Incomplete recovery at end of study

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV plus CS or placebo</th>
<th>CS or placebo</th>
<th>Risk Ratio M-H, Random 95% CI</th>
<th>Weight M-H, Random</th>
<th>Risk Ratio M-H, Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adour 1996</td>
<td>7/53</td>
<td>13/46</td>
<td>9.3 %</td>
<td>0.47 [0.20, 1.07]</td>
<td></td>
</tr>
<tr>
<td>Engström 2008</td>
<td>42/206</td>
<td>50/210</td>
<td>22.7 %</td>
<td>0.86 [0.60, 1.23]</td>
<td></td>
</tr>
<tr>
<td>Hato 2007</td>
<td>4/114</td>
<td>111/107</td>
<td>5.8 %</td>
<td>0.34 [0.11, 1.04]</td>
<td></td>
</tr>
<tr>
<td>Kawaguchi 2007</td>
<td>8/84</td>
<td>9/66</td>
<td>8.3 %</td>
<td>0.70 [0.29, 1.71]</td>
<td></td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>9/124</td>
<td>5/127</td>
<td>6.3 %</td>
<td>1.84 [0.64, 5.35]</td>
<td></td>
</tr>
<tr>
<td>Yeo 2008</td>
<td>3/44</td>
<td>7/47</td>
<td>4.6 %</td>
<td>0.46 [0.13, 1.66]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>625</strong></td>
<td><strong>603</strong></td>
<td>56.9 %</td>
<td>0.71 [0.48, 1.05]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antivirals versus placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engström 2008</td>
<td>74/207</td>
<td>73/206</td>
<td>27.2 %</td>
<td>1.01 [0.78, 1.31]</td>
<td></td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>27/123</td>
<td>18/122</td>
<td>16.0 %</td>
<td>1.49 [0.87, 2.56]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>330</strong></td>
<td><strong>328</strong></td>
<td>43.1 %</td>
<td>1.14 [0.80, 1.62]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>955</strong></td>
<td><strong>931</strong></td>
<td>100.0 %</td>
<td>0.88 [0.65, 1.18]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 95 (AV plus CS or placebo), 95 (CS or placebo)

Heterogeneity: $\tau^2 = 0.07$, $\chi^2 = 7.02$, df = 5 ($P = 0.22$); $I^2 = 29\%$

Test for overall effect: $Z = 1.71$ ($P = 0.087$)

Heterogeneity: $\tau^2 = 0.03$, $\chi^2 = 1.63$, df = 1 ($P = 0.20$); $I^2 = 39\%$

Test for overall effect: $Z = 0.71$ ($P = 0.48$)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 2 Motor synkinesis or crocodile tears.

Review: Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)

Outcome: 2 Motor synkinesis or crocodile tears

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV plus CS or placebo</th>
<th>CS or placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Adour 1996</td>
<td>7/53 13/46</td>
<td></td>
<td>0.47 [0.20, 1.07]</td>
<td>100.0 %</td>
<td>0.47 [0.20, 1.07]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>53 46</td>
<td></td>
<td>100.0 %</td>
<td>0.47 [0.20, 1.07]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 7 (AV plus CS or placebo), 13 (CS or placebo)

Heterogeneity: not applicable

Test for overall effect: Z = 1.80 (P = 0.072)

Analysis 1.3. Comparison 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids), Outcome 3 Adverse Events.

Review: Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

Comparison: 1 Antivirals versus placebo (including antivirals plus corticosteroids versus placebo plus corticosteroids or no treatment plus corticosteroids)

Outcome: 3 Adverse Events

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV plus CS or placebo</th>
<th>CS or placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Engström 2008</td>
<td>50/413 46/416</td>
<td></td>
<td>1.09 [0.75, 1.60]</td>
<td>50.0 %</td>
<td>1.09 [0.75, 1.60]</td>
</tr>
<tr>
<td>Hato 2007</td>
<td>3/114 2/105</td>
<td></td>
<td>1.38 [0.24, 8.11]</td>
<td>2.3 %</td>
<td>1.38 [0.24, 8.11]</td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>44/247 44/249</td>
<td></td>
<td>1.01 [0.69, 1.47]</td>
<td>47.8 %</td>
<td>1.01 [0.69, 1.47]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>774 770</td>
<td></td>
<td>100.0 %</td>
<td>1.06 [0.81, 1.38]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 97 (AV plus CS or placebo), 92 (CS or placebo)

Heterogeneity: Chi² = 0.18, df = 2 (P = 0.91); I² = 0.0%

Test for overall effect: Z = 0.43 (P = 0.67)

Test for subgroup differences: Not applicable
### Analysis 2.1. Comparison 2 Antivirals versus corticosteroids, Outcome 1 Incomplete recovery at end of study.

Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)

Comparison: 2 Antivirals versus corticosteroids

Outcome: 1 Incomplete recovery at end of study

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV n/N</th>
<th>CS n/N</th>
<th>Risk Ratio M-H,Random, 95% CI</th>
<th>Weight %</th>
<th>Risk Ratio M-H,Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Diego 1998</td>
<td>12/54</td>
<td>3/47</td>
<td>26.0 % 3.48 [1.05, 11.60]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engström 2008</td>
<td>74/207</td>
<td>50/210</td>
<td>42.6 % 1.50 [1.11, 2.03]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>27/123</td>
<td>5/127</td>
<td>31.4 % 5.58 [2.22, 14.01]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>384</strong></td>
<td><strong>384</strong></td>
<td><strong>100.0 % 2.82 [1.09, 7.32]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 113 (AV), 58 (CS)
Heterogeneity: Tau² = 0.53; Chi² = 8.78, df = 2 (P = 0.01); I² = 77%
Test for overall effect: Z = 2.13 (P = 0.033)

### Analysis 2.2. Comparison 2 Antivirals versus corticosteroids, Outcome 2 Motor synkinesis at end of study.

Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)

Comparison: 2 Antivirals versus corticosteroids

Outcome: 2 Motor synkinesis at end of study

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV n/N</th>
<th>CS n/N</th>
<th>Risk Ratio M-H,Fixed, 95% CI</th>
<th>Weight %</th>
<th>Risk Ratio M-H,Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Diego 1998</td>
<td>13/54</td>
<td>11/47</td>
<td>100.0 % 1.03 [0.51, 2.07]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>54</strong></td>
<td><strong>47</strong></td>
<td><strong>100.0 % 1.03 [0.51, 2.07]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 13 (AV), 11 (CS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
### Analysis 2.3. Comparison 2 Antivirals versus corticosteroids, Outcome 3 Adverse Events.

**Review:** Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

**Comparison:** 2 Antivirals versus corticosteroids

**Outcome:** 3 Adverse Events

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV</th>
<th>CS</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engström 2008</td>
<td>23/207</td>
<td>21/210</td>
<td>1.11 [0.63, 1.94]</td>
<td>46.9 %</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>19/123</td>
<td>24/127</td>
<td>0.82 [0.47, 1.41]</td>
<td>53.1 %</td>
<td>M-H,Fixed,95% CI</td>
</tr>
</tbody>
</table>

**Total (95% CI):** 330/337, 100.0 %, 0.96 [0.65, 1.41]

Total events: 42 (AV), 45 (CS)

Heterogeneity: $\chi^2 = 0.59$, df = 1 ($P = 0.44$); $I^2 = 0.0$

Test for overall effect: $Z = 0.23$ ($P = 0.82$)

Test for subgroup differences: Not applicable

---

### Analysis 3.1. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 1 Incomplete recovery at end of study.

**Review:** Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

**Comparison:** 3 Antivirals plus corticosteroids versus placebo

**Outcome:** 1 Incomplete recovery at end of study

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV plus CS</th>
<th>placebo/ no treatment</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engström 2008</td>
<td>42/206</td>
<td>73/206</td>
<td>0.58 [0.41, 0.80]</td>
<td>80.1 %</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>9/124</td>
<td>18/122</td>
<td>0.49 [0.23, 1.05]</td>
<td>19.9 %</td>
<td>M-H,Fixed,95% CI</td>
</tr>
</tbody>
</table>

**Total (95% CI):** 330/328, 100.0 %, 0.56 [0.41, 0.76]

Total events: 51 (AV plus CS), 91 (placebo/ no treatment)

Heterogeneity: $\chi^2 = 0.14$, df = 1 ($P = 0.71$); $I^2 = 0.0$

Test for overall effect: $Z = 3.79$ ($P = 0.00015$)

Test for subgroup differences: Not applicable

---

Antiviral treatment for Bell's palsy (idiopathic facial paralysis) (Review) 27

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Antivirals plus corticosteroids versus placebo, Outcome 2 Adverse Effects.

Review: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis)

Comparison: 3 Antivirals plus corticosteroids versus placebo

Outcome: 2 Adverse Effects

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>AV plus CS n/N</th>
<th>placebo/no treatment n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight %</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engström 2008</td>
<td>27/206</td>
<td>25/206</td>
<td>1.08 [0.65, 1.80]</td>
<td>55.4</td>
<td></td>
</tr>
<tr>
<td>Sullivan 2007</td>
<td>25/124</td>
<td>20/122</td>
<td>1.23 [0.72, 2.09]</td>
<td>44.6</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>330</strong></td>
<td><strong>328</strong></td>
<td>1.15 [0.79, 1.66]</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 52 (AV plus CS), 45 (placebo/no treatment)

Heterogeneity: $\chi^2 = 0.12, df = 1 \ (P = 0.73); I^2 = 0.0$

Test for overall effect: $Z = 0.73 \ (P = 0.46)$

Test for subgroup differences: Not applicable

ADDITIONAL TABLES

Table 1. House-Brackmann Scale

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Normal</td>
</tr>
<tr>
<td>II</td>
<td>Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis</td>
</tr>
<tr>
<td>III</td>
<td>Moderate dysfunction; obvious but not disfiguring difference between the two sides; noticeable but not severe synkinesis</td>
</tr>
<tr>
<td>IV</td>
<td>Moderately severe dysfunction; obvious weakness and/or disfiguring asymmetry</td>
</tr>
<tr>
<td>V</td>
<td>Only barely perceptible motion</td>
</tr>
<tr>
<td>VI</td>
<td>No movement</td>
</tr>
</tbody>
</table>

### Table 2. Yanaghara scale

<table>
<thead>
<tr>
<th>Mode</th>
<th>Degree of paralysis</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>4 total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At rest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wrinkle forehead</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blink</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal closure of eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forced closure of eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Closure of eye on involved side</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wrinkle nose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whistle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depress lower lip/ blow out cheek</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ten separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score 0 (total paralysis) to 4 (normal), then summed, giving a total score from 0 (total paralysis) to 40 (normal function).


### Table 3. Sunnybrook Scale

<table>
<thead>
<tr>
<th>Facial Grading System</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Symmetry</td>
<td></td>
</tr>
<tr>
<td>Compared to Normal Side</td>
<td>Degree of muscle EXCURSION compared to normal side</td>
</tr>
<tr>
<td>Eye</td>
<td>STANDARD EXPRESSIONS Forehead Wrinkle</td>
</tr>
</tbody>
</table>
### Table 3. Sunnybrook Scale (Continued)

<table>
<thead>
<tr>
<th></th>
<th>Gentle eye closure</th>
<th>Open mouth smile</th>
<th>Snarl</th>
<th>Lip Pucker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal = 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narrow = 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wide = 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eyelid surgery = 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cheek

<table>
<thead>
<tr>
<th></th>
<th>Normal = 0</th>
<th>Absent = 2</th>
<th>Less pronounced = 1</th>
<th>More pronounced = 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal = 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent = 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less pronounced = 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>More pronounced = 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mouth

<table>
<thead>
<tr>
<th></th>
<th>Normal = 0</th>
<th>Corner drooped = 1</th>
<th>Corner pulled up/out = 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal = 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corner drooped = 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corner pulled up/out = 1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOTAL</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Symmetry Score x 5</td>
<td>Voluntary Movement Score Total x 4</td>
<td>Synkinesis Score</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Voluntary Movement Score - Resting Symmetry Score - Synkinesis Score = Composite Score**

Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function). See Ross et al (1996).

Appendix 1. MEDLINE search strategy

1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized controlled trials/
4 random allocation/
5 double-blind method/
6 single-blind method/
7 or/1-6
8 animals/ not humans/
9 7 not 8
10 clinical trial.pt.
11 exp clinical trial/
12 (clin$ adj25 trial$).ti,ab.
13 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab.
14 placebo/
15 placebo$ .ti,ab.
16 random$ .ti,ab.
17 research design/
18 or/10-17
19 18 not 8
20 19 not 9
21 comparative study/
22 exp evaluation studies/
23 follow up studies/
24 prospective studies/
25 (control$ or prospectiv$ or volunteer$).ti,ab.
26 or/21-25
27 26 not 8
28 27 not (9 or 20)
29 9 or 20 or 28
30 exp Facial Nerve Diseases/
31 bell palsy/
32 facial paralysis/ or hemifacial spasm/
33 ((Bell$ or facial$ or hemifacial$ or unilateral$ or nerve$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (21743)
34 30 or 31 or 32
35 34 or 35
36 Acyclovir/
37 exp Acyclovir/
38 (aciclovir$ or valaciclovir$).mp.
39 (acyclovir$ or valacyclovir$).mp.
40 36 or 37 or 38 or 39
41 29 and 35 and 40
42 limit 41 to ed=20071015-20081210
43 from 42 keep 1-5
Appendix 2. EMBASE search strategy

1 Randomized Controlled Trial/
2 Clinical Trial/
3 Multicenter Study/
4 Controlled Study/
5 Crossover Procedure/
6 Double Blind Procedure/
7 Single Blind Procedure/
8 exp RANDOMIZATION/
9 Major Clinical Study/
10 PLACEBO/
11 Meta Analysis/
12 phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
13 (clin$ adj25 trial$).tw.
14 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
15 placebo$ .tw.
16 random$.tw.
17 control$.tw.
18 (meta?analys$ or systematic review$).tw.
19 (cross?over or factorional or sham$ or dummy$).tw.
20 ABAB design$.tw.
21 or/1-20
22 human/
23 nonhuman/
24 22 or 23
25 21 not 24
26 21 and 22
27 25 or 26
28 exp Nerve Paralysis/
29 bell palsy/
30 facial nerve paralysis/ or hemifacial spasm/
31 ((Bell$ or facial$ or hemifacial$ or unilateral$ or cranial$ or nerve$) adj3 (pals$ or paralyzed$ or paresi$ or spasm$)).mp.
32 or/28-31
33 ACICLOVIR/
34 (aciclovir$ or valaciclovir$).mp.
35 (acyclovir$ or valacyclovir$).mp.
36 33 or 34 or 35
37 27 and 32 and 36
38 limit 37 to em=200742-200850
39 from 38 keep 1-31

Appendix 3. LILACS search strategy

Facial Nerve Diseases or bell palsy or facial paralysis hemifacial spasm or ((Bell or bells or facial or hemifacial or unilateral or nerve or cranial) and (palsy or palsies or paralysis or paresis$ or spasm or spasms)) [Words] and Acyclovir or ganciclovir or aciclovir or acyclovir or valacyclovir [Words] and ((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animals AND NOT (Ct humans and Ct animals)) OR (Pt clinical trial OR Ex E05,318.760,535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw random$ OR Tw casual$ OR Tw asa$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animals AND NOT (Ct humans and Ct animals)) OR (Ct comparative study OR Ex E05,337$ OR Mh follow-up

Antiviral treatment for Bell’s palsy (idiopathic facial paralysis) (Review)

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animals AND NOT (Ct humans and Ct animals))) [Words]

WHAT'S NEW

Last assessed as up-to-date: 24 February 2009.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 May 2010</td>
<td>Amended</td>
<td>Correction to reference</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 3, 1999
Review first published: Issue 2, 2001

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 November 2009</td>
<td>Amended</td>
<td>Correction of minor error in Discussion.</td>
</tr>
<tr>
<td>25 February 2009</td>
<td>New citation required and conclusions have changed</td>
<td>This is a substantive update to the previous edition of the review with a new review team. Five new studies added to the analysis with changes made to Results and Discussion sections as necessary.</td>
</tr>
<tr>
<td>5 February 2009</td>
<td>New search has been performed</td>
<td>Substantive update to previous edition of review. Abstract and background information re-written. Modification of outcomes: all data from trials, whatever the trial length as opposed to 6 month outcomes. Five new studies added to the analysis with necessary changes made to Results and Discussion sections. One study removed from the previous review as no data contributed and none forthcoming to previous authors when approached.</td>
</tr>
<tr>
<td>1 November 2007</td>
<td>Amended</td>
<td>Two trials, one with 551 participants comparing prednisolone with acyclovir with both and with neither, another with 221 participants comparing prednisolone and valacyclovir with prednisolone and placebo have just been published and will be included in an update of this review.</td>
</tr>
<tr>
<td>1 March 2004</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment.</td>
</tr>
</tbody>
</table>
The review was updated in January 2004. Searches were updated as follows: Neuromuscular Disease Group Trials Register (searched April 2003), MEDLINE (searched January 1966 to April 2003), EMBASE (searched January 1980 to April 2003), and LILACS (searched January 1982 to April 2003).

**Contributions of Authors**

All authors contributed to the review and data extraction process. Dr F Daly wrote the first draft of the report with all clinical inputs from Professor F Sullivan and Dr P Lockhart. Dr P Lockhart incorporated the work into the existing review and was responsible for risk of bias assessment, data analysis and use of the RevMan software.

**Declarations of Interest**

Dr F Daly and Professor F Sullivan are named authors on one of the included studies (Sullivan 2007).

**Sources of Support**

Internal sources

- University of Dundee, UK.

External sources

- No sources of support supplied

**Differences between Protocol and Review**

There are several differences between the published review protocol and this version of the review. These mainly reflect the changes over time to the treatment options and Cochrane methodology. The search for studies now includes treatment with valaciclovir and famciclovir, either alone or in combination with any other therapy, to reflect the treatment options now available for Bell's palsy. The methodological assessment has been undertaken according to the latest Cochrane guidance, detailed in the Cochrane Handbook for Systematic Reviews of Interventions Chapter 8. Criteria for judging study quality are sequence generation, allocation concealment, blinding of participants and outcome assessors, selective outcome reporting and other sources of bias. The criteria are assessed as 'Yes', indicating a low likelihood of bias, 'No', indicating a high likelihood of bias or 'Unclear' where information is not sufficient to make a judgement. Other sources of bias which are considered includes diagnostic criteria, outcome criteria, baseline differences between groups and completeness of follow up. All five authors were given a selection of papers to read, review for quality and extract data from. The work was distributed so that each paper was reviewed by at least two authors. PL performed the final risk of bias quality assessment procedure which was independently reviewed by FS and FD.

We have focused this search on immunocompetent patients, which was not stipulated in the original protocol. This has been done as treatment protocols for immunocompromised individuals and treatment response may differ significantly from other individuals and, as such, cannot be fully explored in this analysis.
We have widened the outcome criteria to include outcomes at the end of the study as opposed to one year or six months after treatment. This is to allow inclusion of a maximal number of published studies. It is understood that this may introduce significant heterogeneity to the results and a sensitivity analysis looking at outcomes in participants in studies reporting at 12 weeks or less and six months or less was included in order to assess the influence this had on the robustness of published results.

**INDEX TERMS**

**Medical Subject Headings (MeSH)**

Acyclovir [analogs & derivatives; *therapeutic use*]; Anti-Inflammatory Agents [*therapeutic use*]; Antiviral Agents [*therapeutic use*]; Bell Palsy [*drug therapy; virology*]; Drug Therapy, Combination [methods]; Herpes Simplex [complications; *drug therapy*]; Prednisolone [therapeutic use]; Randomized Controlled Trials as Topic; Valine [analogs & derivatives; therapeutic use]

**MeSH check words**

Humans